Puma Biotechnology is a publicly-traded pharmaceutical company (NASDAQGS: PBYI) headquartered in Los Angeles, CA. Puma in-licenses intermediate-stage drug candidates for further development. The company was founded in 2010. The current CEO is Alan Auerbach.
Currently Puma licenses three drug candidates from Pfizer: PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is an irreversible tyrosine kinase inhibitor blocking EGFR, HER1, HER2, and HER4. A new drug application was filed with the FDA for oral neratinib in July 2016.
As of December 31, 2015, they had 156 full-time employees.